ADMA Biologics Inc (ADMA)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 125,714 | -28,239 | -65,904 | -71,648 | -75,749 |
| Revenue | US$ in thousands | 426,454 | 258,215 | 154,080 | 80,943 | 42,220 |
| Pretax margin | 29.48% | -10.94% | -42.77% | -88.52% | -179.41% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $125,714K ÷ $426,454K
= 29.48%
The pretax margin of ADMA Biologics Inc has shown a significant improvement over the years based on the provided data. The company experienced negative pretax margins in the fiscal years ending December 31, 2020, 2021, 2022, and 2023, with values of -179.41%, -88.52%, -42.77%, and -10.94% respectively. However, there was a notable turnaround in the fiscal year ending December 31, 2024, where the pretax margin turned positive at 29.48%.
This improvement in pretax margin suggests that ADMA Biologics Inc has been able to enhance its operating efficiency, control costs, or increase revenue generation to achieve profitability before taxes. It is essential for the company to sustain this positive trend in pretax margins to ensure long-term financial health and sustainable growth.
Peer comparison
Dec 31, 2024